Status: Not yet recruiting
A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy
Immune resistance after treatment, there is no standard treatment, one of the most important and the most effective measures is immune to combination therapy。Targeted angiogenesis therapy has always been the focus of research on the treatment of NSCLC patients with progressive disease after immunotherapy. From the mechanism of action, angiogenesis and immunosuppression are interrelated processes.
Participants needed: 33
Trial details
Phase: Phase 4Age: 18-75Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital, Guangzhou University of Traditional Chinese MedicineUpdated: Apr 10, 2024
Eligibility criteria
voluntary participation in clinical research; Fully understand and Informed the... [+7]
Frontline treatment with anlotinib, anti-angiogenic macromolecular monoclonal an... [+8]